Generation of a Novel High-Affinity Antibody Binding to PCSK9 Catalytic Domain with Slow Dissociation Rate by CDR-Grafting, Alanine Scanning and Saturated Site-Directed Mutagenesis for Favorably Treating Hypercholesterolemia

Inhibition of proprotein convertase subtilisin/kexin type 9 (PCSK9) has become an attractive therapeutic strategy for lowering low-density lipoprotein cholesterol (LDL-C). In this study, a novel high affinity humanized IgG1 mAb (named h5E12-L230G) targeting the catalytic domain of human PCSK9 (hPCSK...

Descripción completa

Detalles Bibliográficos
Autores principales: Bai, Zhengli, Xu, Menglong, Mei, Ying, Hu, Tuo, Zhang, Panpan, Chen, Manman, Lv, Wenxiu, Lu, Chenchen, Tan, Shuhua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8698692/
https://www.ncbi.nlm.nih.gov/pubmed/34944600
http://dx.doi.org/10.3390/biomedicines9121783

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8698692/
https://www.ncbi.nlm.nih.gov/pubmed/34944600
http://dx.doi.org/10.3390/biomedicines9121783

Ejemplares similares